1125 related articles for article (PubMed ID: 18772034)
1. Neuropharmacology of second-generation antipsychotic drugs: a validity of the serotonin-dopamine hypothesis.
Kuroki T; Nagao N; Nakahara T
Prog Brain Res; 2008; 172():199-212. PubMed ID: 18772034
[TBL] [Abstract][Full Text] [Related]
2. [Pharmacology of second-generation antipsychotics: a validity of the serotonin-dopamine hypothesis].
Kuroki T
Nihon Shinkei Seishin Yakurigaku Zasshi; 2004 Oct; 24(5):257-64. PubMed ID: 15658501
[TBL] [Abstract][Full Text] [Related]
3. In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems.
Meltzer HY; Huang M
Prog Brain Res; 2008; 172():177-97. PubMed ID: 18772033
[TBL] [Abstract][Full Text] [Related]
4. Serotonin receptors: their key role in drugs to treat schizophrenia.
Meltzer HY; Li Z; Kaneda Y; Ichikawa J
Prog Neuropsychopharmacol Biol Psychiatry; 2003 Oct; 27(7):1159-72. PubMed ID: 14642974
[TBL] [Abstract][Full Text] [Related]
5. The role of serotonin receptors in the action of atypical antipsychotic drugs.
Meltzer HY; Massey BW
Curr Opin Pharmacol; 2011 Feb; 11(1):59-67. PubMed ID: 21420906
[TBL] [Abstract][Full Text] [Related]
6. Role of serotonin and dopamine receptor binding in antipsychotic efficacy.
Richtand NM; Welge JA; Logue AD; Keck PE; Strakowski SM; McNamara RK
Prog Brain Res; 2008; 172():155-75. PubMed ID: 18772032
[TBL] [Abstract][Full Text] [Related]
7. Atypical antipsychotics: mechanism of action.
Seeman P
Can J Psychiatry; 2002 Feb; 47(1):27-38. PubMed ID: 11873706
[TBL] [Abstract][Full Text] [Related]
8. Long-term effects of JL 13, a potential atypical antipsychotic, on rat dopamine and serotonin receptor subtypes.
Moran-Gates T; Massari C; Graulich A; Liégeois JF; Tarazi FI
J Neurosci Res; 2006 Aug; 84(3):675-82. PubMed ID: 16810690
[TBL] [Abstract][Full Text] [Related]
9. F15063, a potential antipsychotic with dopamine D(2)/D(3) receptor antagonist and 5-HT(1A) receptor agonist properties: influence on immediate-early gene expression in rat prefrontal cortex and striatum.
Bruins Slot LA; Lestienne F; Grevoz-Barret C; Newman-Tancredi A; Cussac D
Eur J Pharmacol; 2009 Oct; 620(1-3):27-35. PubMed ID: 19695244
[TBL] [Abstract][Full Text] [Related]
10. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity.
Seeger TF; Seymour PA; Schmidt AW; Zorn SH; Schulz DW; Lebel LA; McLean S; Guanowsky V; Howard HR; Lowe JA
J Pharmacol Exp Ther; 1995 Oct; 275(1):101-13. PubMed ID: 7562537
[TBL] [Abstract][Full Text] [Related]
11. Contrasting contribution of 5-hydroxytryptamine 1A receptor activation to neurochemical profile of novel antipsychotics: frontocortical dopamine and hippocampal serotonin release in rat brain.
Assié MB; Ravailhe V; Faucillon V; Newman-Tancredi A
J Pharmacol Exp Ther; 2005 Oct; 315(1):265-72. PubMed ID: 15987834
[TBL] [Abstract][Full Text] [Related]
12. Improving the treatment of schizophrenia: focus on serotonin (5-HT)(1A) receptors.
Millan MJ
J Pharmacol Exp Ther; 2000 Dec; 295(3):853-61. PubMed ID: 11082417
[TBL] [Abstract][Full Text] [Related]
13. Role of serotonin in the action of atypical antipsychotic drugs.
Meltzer HY
Clin Neurosci; 1995; 3(2):64-75. PubMed ID: 7583621
[TBL] [Abstract][Full Text] [Related]
14. Stimulation by antipsychotic agents of mitogen-activated protein kinase (MAPK) coupled to cloned, human (h)serotonin (5-HT)(1A) receptors.
Cussac D; Duqueyroix D; Newman-Tancredi A; Millan MJ
Psychopharmacology (Berl); 2002 Jul; 162(2):168-77. PubMed ID: 12110994
[TBL] [Abstract][Full Text] [Related]
15. Dopamine and serotonin interactions in the prefrontal cortex: insights on antipsychotic drugs and their mechanism of action.
Di Pietro NC; Seamans JK
Pharmacopsychiatry; 2007 Dec; 40 Suppl 1():S27-33. PubMed ID: 18080940
[TBL] [Abstract][Full Text] [Related]
16. Antipsychotic drugs reverse the AMPA receptor-stimulated release of 5-HT in the medial prefrontal cortex.
Amargós-Bosch M; Adell A; Artigas F
J Neurochem; 2007 Jul; 102(2):550-61. PubMed ID: 17394545
[TBL] [Abstract][Full Text] [Related]
17. Differential effects of antipsychotic drugs on serotonin-1A receptor-mediated disruption of prepulse inhibition.
van den Buuse M; Gogos A
J Pharmacol Exp Ther; 2007 Mar; 320(3):1224-36. PubMed ID: 17194799
[TBL] [Abstract][Full Text] [Related]
18. Antipsychotics differ in their ability to internalise human dopamine D2S and human serotonin 5-HT1A receptors in HEK293 cells.
Heusler P; Newman-Tancredi A; Loock T; Cussac D
Eur J Pharmacol; 2008 Feb; 581(1-2):37-46. PubMed ID: 18190908
[TBL] [Abstract][Full Text] [Related]
19. Affinity of cyamemazine metabolites for serotonin, histamine and dopamine receptor subtypes.
Benyamina A; Arbus C; Nuss P; Garay RP; Neliat G; Hameg A
Eur J Pharmacol; 2008 Jan; 578(2-3):142-7. PubMed ID: 17936750
[TBL] [Abstract][Full Text] [Related]
20. Pyrrolo[1,3]benzothiazepine-based serotonin and dopamine receptor antagonists. Molecular modeling, further structure-activity relationship studies, and identification of novel atypical antipsychotic agents.
Campiani G; Butini S; Fattorusso C; Catalanotti B; Gemma S; Nacci V; Morelli E; Cagnotto A; Mereghetti I; Mennini T; Carli M; Minetti P; Di Cesare MA; Mastroianni D; Scafetta N; Galletti B; Stasi MA; Castorina M; Pacifici L; Vertechy M; Di Serio S; Ghirardi O; Tinti O; Carminati P
J Med Chem; 2004 Jan; 47(1):143-57. PubMed ID: 14695828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]